سعر ازولميجرا 5 مجم 2 قرص 2024

Azolmigra: zolmitriptan 5 mg orodispersible tablets, pack of 2; selective 5-HT1B/1D agonist (triptan) antimigraine. Company: MUP.

• Acute treatment of migraine with or without auraPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (>=5% and more than placebo): neck/throat/jaw pain, dizziness, paresthesia, asthenia, somnolence, warm/cold sensation, nausea, heaviness sensation and dry mouth; several appear dose related. Hypersensitivity reactions including anaphylaxis and angioedema reported postmarketing.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Ischemic coronary artery disease, other significant cardiovascular disease, or coronary vasospasm including Prinzmetal angina; Wolff-Parkinson-White syndrome or other accessory conduction pathway arrhythmias.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• History of stroke, transient ischemic attack, or hemiplegic or basilar migraine; peripheral vascular disease; ischemic bowel disease; uncontrolled hypertension.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Use within 24 hours of another 5-HT1 agonist or ergot-type medication; concurrent MAO-A inhibitor or use within 2 weeks; known hypersensitivity to zolmitriptan.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Myocardial ischemia/infarction and Prinzmetal angina have occurred; perform cardiovascular evaluation in triptan-naive patients with multiple risk factors before use.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Life-threatening arrhythmias, chest/throat/neck/jaw tightness, cerebrovascular events and other vasospastic reactions (peripheral, gastrointestinal ischemia, Raynaud) have been reported.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Medication overuse headache with use on 10 or more days per month; serotonin syndrome, particularly with SSRIs, SNRIs, TCAs and MAO inhibitors; significant blood pressure elevations.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Ergot-containing drugs and other 5-HT1B/1D agonistsAdditive vasospastic effects; use within 24 hours of each other is contraindicated.DailyMed (U.S. National Library of Medicine)
• MAO-A inhibitorsIncrease systemic exposure to zolmitriptan and its active metabolite; contraindicated (including within 2 weeks of stopping).DailyMed (U.S. National Library of Medicine)
• SSRIs and SNRIsLife-threatening serotonin syndrome has been reported with co-administration of triptans.DailyMed (U.S. National Library of Medicine)

• No adequate data on developmental risk in pregnant women. In rats and rabbits, oral zolmitriptan caused embryolethality and fetal abnormalities at clinically relevant exposures. Women with migraine may be at increased risk of preeclampsia.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk or effects on the breastfed infant or milk production; in rats milk levels were up to 4 times maternal plasma. Weigh benefits of breastfeeding against the mother's clinical need.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Zolmitriptan: Agonist at 5-HT1B/1D receptors on intracranial blood vessels and trigeminal sensory nerves, causing cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.